126 related articles for article (PubMed ID: 11446564)
1. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss.
Rymer J; Robinson J; Fogelman I
Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.
Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ
Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157
[TBL] [Abstract][Full Text] [Related]
3. Tibolone and osteoporosis.
Lazovic G; Radivojevic U; Milosevic V; Lazovic A; Jeremic K; Glisic A
Arch Gynecol Obstet; 2007 Dec; 276(6):577-81. PubMed ID: 17605023
[TBL] [Abstract][Full Text] [Related]
4. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women.
Rymer J; Robinson J; Fogelman I
Climacteric; 2002 Dec; 5(4):390-8. PubMed ID: 12626219
[TBL] [Abstract][Full Text] [Related]
5. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures.
Studd J; Arnala I; Kicovic PM; Zamblera D; Kröger H; Holland N
Obstet Gynecol; 1998 Oct; 92(4 Pt 1):574-9. PubMed ID: 9764631
[TBL] [Abstract][Full Text] [Related]
7. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up.
Prelevic GM; Markou A; Arnold A; Bartram C; Puzigaca Z; Ginsburg J
Maturitas; 2004 Mar; 47(3):229-34. PubMed ID: 15036493
[TBL] [Abstract][Full Text] [Related]
8. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women.
Reginster JY; Agnusdei D; Gennari C; Kicovic PM
Gynecol Endocrinol; 1999 Oct; 13(5):361-8. PubMed ID: 10599554
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
10. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial.
Beardsworth SA; Kearney CE; Purdie DW
Br J Obstet Gynaecol; 1999 Jul; 106(7):678-83. PubMed ID: 10428524
[TBL] [Abstract][Full Text] [Related]
11. Effect of tibolone on postmenopausal bone loss.
Rymer J; Chapman MG; Fogelman I
Osteoporos Int; 1994 Nov; 4(6):314-9. PubMed ID: 7696824
[TBL] [Abstract][Full Text] [Related]
12. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.
Gallagher JC; Baylink DJ; Freeman R; McClung M
J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531
[TBL] [Abstract][Full Text] [Related]
13. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
Uretmen S; Gol M; Cimrin D; Irmak E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
[TBL] [Abstract][Full Text] [Related]
15. Effects of tibolone (Org OD14) treatment for 3 months on ovariectomy-induced osteopenia in 8-month-old rats on a low-calcium diet: preventive testing for 3 months.
Kasugai Y; Ikegami A; Matsuo K; Ohashi M; Sukamoto T; Hosoi T; Ouchi Y; Orimo H
Bone; 1998 Feb; 22(2):119-24. PubMed ID: 9477234
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
18. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
19. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
[TBL] [Abstract][Full Text] [Related]
20. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
